C-reactive protein tests measure the levels of C-reactive protein produced by the liver through a blood test, which monitors infection in the body that causes diseases such as cancer, cardiovascular disease, arthritis, and so on. In the coming years, market growth will be driven by rising demand for minimally invasive diagnostics. The worldwide C – reactive protein market was worth $2.76 billion in 2021 and will reach $3.42 billion by 2030 with a 2.4% CAGR during 2021-2030.
The rise in prevalence of inflammatory diseases, diabetes, and cancers; the rising incidence of endometriosis in women around the world; the increase in funding for technological development in diagnostics; and the increase in acceptance of point-of-care devices are the primary factors driving the growth of the C-reactive Protein Testing Market.
According to data published by the Centers for Disease Control and Prevention and updated in July 2022, there are approximately 20.1 million adults in the United States aged 20 and older who have coronary artery disease. It also stated that every year, about 805,000 people in the US experience a heart attack. The increased incidences of cardiovascular problems will increase the use of CRP testing to detect the risk of cardiovascular disease, boosting market expansion.
Furthermore, along with the rising incidence of cardiovascular disease, rapidly increasing product launches for point-of-care CRP testing will accelerate the growth of this market over the forecast period.
Must Read : is delmicron a new variant of covid-19
The availability of alternative testing methods for diseases with higher accuracy rates, such as the electrocardiogram (ECG), and echocardiogram (ultrasound), in terms of screening for various cardiac diseases and a variety of other products for other diseases, will hamper the market’s overall growth.
New emerging markets are likely to have significant growth potential as a result of improved healthcare infrastructure, rising unmet healthcare demand, and increased R&D efforts. Furthermore, significant technological advancements in rapid diagnostic kits are opening up a new avenue for major competitors to enter the c-reactive protein testing market.
Assay type Insights
In 2020, immunoturbidimetric assays dominated the market and accounted for 48.5% of total revenue and will grow rapidly during the anticipated time. In the upcoming years, the use of this technique for various chronic cardiac and respiratory disorders will contribute to the segment’s largest market share.
Detection Range Insights
In 2020, the hs-CRP segment held a significant position with a revenue share of 42.8% in the CRP testing market. From 2021 to 2028, the segment is project to grow at a CAGR of 0.3%. This test has a lower detection range than traditional methods and offers results that are more accurate than those provided by standard CRP-based assays. High sensitivity CRP has a detection range of 10 mg/L to >10.0 mg/L.
As per the American Heart Association and the Centers for Disease Control and Prevention (CDC), hs-CRP is an independent marker that aids in diagnosing cardiovascular diseases such as myocardial infarction.
Disease Type Insights
The cardiovascular diseases (CVD) segment ruled the market, with a 21.8% market share in 2020. An increase in the incidence of CVDs is the primary factor stimulating the growth of this segment. A few risk factors for CVDs include a sedentary lifestyle, obesity, hypertension, and diabetes. C-reactive protein has been identified as the most widely studied noninvasive biomarker for inflammation in CVDs, with several hs-CRP assays currently on the market.
In 2020, the hospital sector ruled the market and had the highest revenue share of 27.2%. The increasing penetration of CRP testing in hospitals, particularly in developing regions around the world, can be attribute to the segment’s growth. The adoption of CRP testing kits has increased as a result of an increase in hospital visits brought on by the occurrence of COVID-19. Cardiovascular conditions, and cancer-related infections.
With a revenue share of 39.5% in 2020, North America ruled the C-reactive protein testing market. The increasing use of cutting-edge technology and a strong emphasis on clinical research in North America are two factors propelling the market. Because of the high cancer prevalence in the United States, CRP tests are widely used.
Key Players analysis
- Abbott Laboratories
- Randox Laboratoroes Ltd.
- Siemens Healthineers AG
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Quest Diagnostics
- Ortho Clinical Diagnostics
- Other Players